entertainment -WSS

entertainment

author：focus 2025-10-02 11:09:25 - browse：3552

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

The firm also said that it would be raising $500 million through a stock sale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why the quest to eradicate polio has stumbled

hotspot

WSS

What health policies could hitch a ride on a spending bill?

Ohio still needs to do more to protect the right to abortion

Covid’s new normal has set in amid another rise in cases

Healthy food access boosts outcomes in two studies

UnitedHealth sued over use of algorithm in Medicare Advantage plans

The struggle to figure out which patients 'deserve' Wegovy

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Continuity nursing helped my family in our darkest PICU moments

Ohio still needs to do more to protect the right to abortion

Medicare details structure of new drug price negotiation program

A letter from the executive editor: STAT UnitedHealth investigation

23andMe had bad news about my health. I wish a person had delivered it

FDA weighs limits of animal data in assessing artificial wombs

Medicare details structure of new drug price negotiation program

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Drug repurposing or repositioning? The language matters

CVS, Rite Aid closures threaten to worsen pharmacy deserts

leisure time

Ventyx halts psoriasis drug development after lackluster trial results

After decades in use, heart stents finally beat placebo

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Weight loss drugs should be covered by insurers, AMA says

People with substance use disorder deserve online privacy

Patients, doctors press FTC to beef up hospital merger scrutiny

explore

hotspot

entertainment

entertainment